CPHA Canvax

"COVID-19 vaccination during pregnancy is recommended to prevent severe illness and death in pregnant women. Infants are at risk for COVID-19–associated complications, including respiratory failure and other life-threatening complications.

Effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization among infants aged <6 months was 61% (95% CI = 31% to 78%). Effectiveness of completion of the primary COVID-19 vaccine series early and later in pregnancy was 32% (95% CI = –43% to 68%) and 80% (95% CI = 55% to 91%), respectively.

Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months." - Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Additional Authors: Julie A. Boom, Leila C. Sahni, Melissa A. Cameron, Pia S. Pannaraj, Katherine E. Bline, Samina S. Bhumbra, Tamara T. Bradford, Kathleen Chiotos, Bria M. Coates, Melissa L. Cullimore, Natalie Z. Cvijanovich, Heidi R. Flori, Shira J. Gertz, Sabrina M. Heidemann, Charlotte V. Hobbs, Janet R. Hume, Katherine Irby, Satoshi Kamidani, Michele Kong, Emily R. Levy, Elizabeth H. Mack, Aline B. Maddux, Kelly N. Michelson, Ryan A. Nofziger, Jennifer E. Schuster, Stephanie P. Schwartz, Laura Smallcomb, Keiko M. Tarquinio, Tracie C. Walker, Matt S. Zinter, Suzanne M. Gilboa, Kara N. Polen, Angela P. Campbell, Adrienne G. Randolph, Manish M. Patel

Rating See Comments Ratings

Category:

Vaccine Safety and Development,Research and Development,Vaccine Effectiveness and Efficacy,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Research and Development
Vaccine Effectiveness and Efficacy
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.